Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Jerkeman Mats; Hutchings Martin; Raty Riikka; Wader Karin Fahl; Laurell Anna; Kuitunen Hanne; Toldbod Helle; Pedersen Lone Bredo; Eskelund Christian Winther; Gronbaek Kirsten; Niemann Carsten Utoft; Geisler Christian H.; Kolstad Arne

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

【24h】

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

机译：复发/难治性套细胞淋巴瘤患者的依鲁替尼-来那度胺-利妥昔单抗：北欧淋巴瘤组MCL6（PHILEMON）II期试验的初步结果

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology 》 |2016年第22期| 共4页
作者
Jerkeman Mats; Hutchings Martin; Raty Riikka; Wader Karin Fahl; Laurell Anna; Kuitunen Hanne; Toldbod Helle; Pedersen Lone Bredo; Eskelund Christian Winther; Gronbaek Kirsten; Niemann Carsten Utoft; Geisler Christian H.; Kolstad Arne;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial [J] . Jerkeman Mats, Hutchings Martin, Raty Riikka, Blood: The Journal of the American Society of Hematology . 2016 ,第22期

机译：复发/难治性套细胞淋巴瘤患者的依鲁替尼-来那度胺-利妥昔单抗：北欧淋巴瘤组MCL6（PHILEMON）II期试验的初步结果
2. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial [J] . Delphine Rolland, Vincent Ribrag, Corinne Haioun, Cancer Chemotherapy and Pharmacology . 2010 ,第4期

机译：II期试验和单药替非法尼在复发/难治性套细胞淋巴瘤患者中的反应预测：Groupe d'Etude des Lymphomes de l'Adulte试验
3. Four‐year follow‐up of a single arm, phase II II clinical trial of ibrutinib with rituximab ( IR IR ) in patients with relapsed/refractory mantle cell lymphoma ( MCL MCL ) [J] . Jain Preetesh, Romaguera Jorge, Srour Samer A., British Journal of Haematology . 2018 ,第3期

机译：单臂的四年随访，II期II II II临床试验与Rituximab（IR IR）复发/难治性地幔细胞淋巴瘤（MCL MCL）的患者
4. Mutational profile of Diffuse Large B-cell Lymphoma with central nervous system relapse: analysis of CBioPortal for Cancer Genomics database [C] . Elena Voropaeva, Olga Beresina, Tatyana Pospelova, Conference on Cognitive Sciences, Genomics and Bioinformatics . 2020

机译：弥漫性大B细胞淋巴瘤与中枢神经系统复发的突变特征：用于癌症基因组学数据库的CBioPortal分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma [O] . Michinori Ogura, Kiyoshi Ando, Tatsuya Suzuki, -1

机译：伏立诺他用于多发性或难治性惰性B细胞非霍奇金淋巴瘤和套细胞淋巴瘤患者的多中心II期研究
7. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial [O] . Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, 2018

机译：伊布洛替尼，Lenalidomide和Rituximab在复发或难治性搭式细胞淋巴瘤（腓声）：多期，开放标签，单臂，第2期试验

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

著录项

相似文献

相关主题

期刊订阅